Tesamorelin: A Scientific Review of Mechanisms and Investigational Applications
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone that stimulates the synthesis and release of endogenous growth hormone. Marketed as Egrifta and administered via subcutaneous injection, it received FDA approval in November 2010 as the first and only treatment specifically indicated for reducing excess abdominal fat in patients with HIV-associated lipodystrophy. Phase III randomized controlled […]
